Search Within

Shanu Modi

  1. "Larry Norton"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (26)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (53)
  2. Breast Medicine Service (53)
  3. Department of Medicine (53)
  4. Solid Tumor Oncology Division (53)
  5. Survivorship Research (50)
  6. Epidemiology and Biostatistics (38)

More Groups

People
  1. Larry Norton (53)
  2. Clifford Hudis (42)
  3. Chau Dang (28)
  4. Sujata Patil (24)
  5. Maura Dickler (21)
  6. Diana Lake (19)

More People

Years
  1. 2024 (2)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (6)
  6. 2018 (3)

More Years

Publications
  1. Journal of Clinical Oncology (13)
  2. Cancer Research (12)
  3. Clinical Breast Cancer (5)
  4. Annals of Oncology (4)
  5. Clinical Cancer Research (4)
  6. npj Breast Cancer (3)

More Publications

Publishers
  1. American Association for Cancer Research (17)
  2. American Society of Clinical Oncology (13)
  3. Oxford University Press (6)
  4. Elsevier Inc. (5)
  5. Nature Publishing Group (3)
  6. American Medical Association (2)

More Publishers

Results (53)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab
    Meeting Abstract

    Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results
    Meeting Abstract

    Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
    Cancer Research (2009)

    Fulltext@MSK | Save
  • Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)
    Meeting Abstract

    Dang, C. T.; Lin, N. U.; Lake, D.; Dickler, M. N.; Modi, S.; Seidman, A. D.; Steingart, R. M.; Norton, L.; Winer, E. P.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • A phase I study of cetuximab in combination with paclitaxel in patients with advanced-stage breast cancer
    Journal Article

    Modi, S.; D'Andrea, G.; Norton, L.; Yao, T. J.; Caravelli, J.; Rosen, P. P.; Hudis, C.; Seidman, A. D.
    Clinical Breast Cancer (2006)

    Fulltext@MSK | Save
  • Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
    Meeting Abstract

    Solit, D. B.; Basso, A.; Smith-Jones, P.; Modi, S.; Norton, L.; Larson, S.; Neckers, L.; Scher, H.; Hudis, C.; Rosen, N.
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.; Dickler, M.; Moasser, M.; D'Andrea, G.; Moynahan, M. E.; Menell, J.; Panageas, K. S.; Tan, L. K.; Norton, L.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Journal Article

    Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; more...
    Cancer Investigation (2005)

    Fulltext@MSK | Save
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save